Article

B + L Innovations at AOA

Bausch + Lomb (B+ L), the company that brought the first soft contact lens to market 40 years ago this month, showcased product innovations and scientific research focused on improving patient care, outcomes, and quality of life at the American Optometric Association?s (AOA) annual meeting in Salt Lake City June 15 to 19.

Salt Lake City-Bausch + Lomb (B + L), the company that brought the first soft contact lens to market 40 years ago this month, showcased product innovations and scientific research focused on improving patient care, outcomes, and quality of life at the annual meeting of the American Optometric Association’s (AOA) here earlier this month.

“B + L’s commercialization of the soft contact lens was a major breakthrough for consumers,” said Calvin Roberts, MD, chief medical officer, B + L. “We continue to pursue similar innovations within vision care, surgical and pharmaceutical platforms staying true to our unwavering goal of helping millions of patients around the world see better to live better.”

Innovations showcased by the company at AOA included:

• Biotrue, a bio-inspired contact lens solution that works like the eyes to help lenses stay clean and moist throughout the day.
• PureVision 2 HD contact lenses with precision optics are designed for crisp vision in low light and help reduce halos and glare. 
• Ocuvite 50+, an eye vitamin supplement developed to help replace nutrients the eyes lose with age.    
• Retisert, an intravitreal drug implant for the treatment of chronic non-infectious uveitis that affects the posterior segment of the eye.  
• Alaway, an eye drop designed to provide fast-acting relief from itchiness.

Also, the B + L Web site (www.bausch.com) has been enhanced to provide patients and professionals with in-depth information and resources. The site includes improved navigation and content organization, as well as the addition of mobile and social media links that provide access to additional resources.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
Alex Hacopian, MD, discusses a presbyopia-correcting IOL at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.